Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Real-World Treatment Outcomes of Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated with Pegcetacoplan and Complement Protein 5 Inhibitors (C5i)

Elaine M Majerus, Brian Mulherin, Koo Wilson, Jesse Fishman, Jennifer Mellor, Lucy Earl, Alexander Roeth

Blood (2023) 142 (Supplement 1): 5633.

https://doi.org/10.1182/blood-2023-181921

Published: 2023

Journal Articles

A Matching-Adjusted Indirect Comparison of the Efficacy of Pegcetacoplan Using Prince Trial Data Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria

Raymond Wong, Jesse Fishman, Koo Wilson, Mohammed Al-Adhami, Michael Yeh, Zalmai Hakimi, Christopher Yee, Lynn Huynh, Mei Sheng Duh

Blood (2022) 140 (Supplement 1): 11435–11437.

https://doi.org/10.1182/blood-2022-160197

Published: 2022

Journal Articles

Comparison of Emapalumab with Conventional Treatment in Patients with Primary Hemophagocytic Lymphohistiocytosis (HLH): Consistent Results Obtained in an Unadjusted and an Adjusted Analysis

Sarah Dewilde, Emilia Nivelle, Alison Griffiths, Koo Wilson, Jameel Nazir, Michal Pochopien, Franco Locatelli, MD PhD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-140298

Published: 2020

Journal Articles

Analysis of Hospitalization Events in Patients with Primary Hemophagocytic Lymphohistiocytosis (HLH) Treated with Emapalumab

Koo Wilson, Michal Pochopien, Jameel Nazir, Anupama Rao, Franco Locatelli, MD PhD

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-140348

Published: 2020

Journal Articles

Economic Impact of Immune Tolerance Induction (ITI) with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Compared to Conventional Recombinant Factor VIII (rFVIII)

Nanxin Li, Koo Wilson, Marc Botteman, MS, MA, Daniel Nicoloso, Sangeeta Krishnan, PharmD, Jun Su, MD

Blood (2018) 132 (Supplement 1): 3520.

https://doi.org/10.1182/blood-2018-99-114993

Published: 2018

NARROW

Real-World Treatment Outcomes of Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated with Pegcetacoplan and Complement Protein 5 Inhibitors (C5i)

A Matching-Adjusted Indirect Comparison of the Efficacy of Pegcetacoplan Using Prince Trial Data Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria

Comparison of Emapalumab with Conventional Treatment in Patients with Primary Hemophagocytic Lymphohistiocytosis (HLH): Consistent Results Obtained in an Unadjusted and an Adjusted Analysis

Analysis of Hospitalization Events in Patients with Primary Hemophagocytic Lymphohistiocytosis (HLH) Treated with Emapalumab

Economic Impact of Immune Tolerance Induction (ITI) with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Compared to Conventional Recombinant Factor VIII (rFVIII)

Email alerts

ASH Publications

American Society of Hematology

Real-World Treatment Outcomes of Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated with Pegcetacoplan and Complement Protein 5 Inhibitors (C5i)

A Matching-Adjusted Indirect Comparison of the Efficacy of Pegcetacoplan Using Prince Trial Data Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria

Comparison of Emapalumab with Conventional Treatment in Patients with Primary Hemophagocytic Lymphohistiocytosis (HLH): Consistent Results Obtained in an Unadjusted and an Adjusted Analysis

Analysis of Hospitalization Events in Patients with Primary Hemophagocytic Lymphohistiocytosis (HLH) Treated with Emapalumab

Economic Impact of Immune Tolerance Induction (ITI) with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Compared to Conventional Recombinant Factor VIII (rFVIII)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only